1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Bioray Biotech Co., Ltd

Bioray Biotech Co., Ltd

TTPEX:7561
17.75
TWD
-0.80
(-4.31%)
534.01MMarket Cap
Bioray Biotech Co., Ltd
TPEX:7561
(Taipei Exchange)

Recent

price

17.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
5.83
8.32
6.64
5.7
5.53
6.8
6.38
6.76
7.53
- -
Revenue per Share
0.16
0.98
0.71
- -
-0.27
0.02
-0.38
0.03
1.09
- -
Basic EPS, GAAP
-1.02
-1.79
-0.05
-1.81
-0.25
-2.07
-0.36
0.45
2.41
- -
Free Cash Flow per Basic Share
0.31
- -
0.36
0.29
- -
- -
0.2
- -
- -
- -
Dividend per Share
8
13.59
13.78
13.47
13.28
15.01
14.42
14.22
15.31
14.57
Book Value per Share
7.9
13.57
13.69
13.36
13.16
14.9
14.38
14.19
15.3
14.56
Tangible Book Value per Share
21
22
27
27
27
28
30
30
30
30
Basic Weighted Avg Shares
124
185
182
156
148
191
192
202
223
- -
Sales/Revenue/Turnover
-0.31
6.9
3.72
0.06
-5.48
-0.12
-10.08
-1.93
16.97
- -
Operating Margin (%)
10
10
15
15
19
22
25
25
24
- -
Depreciation Expense
3
22
19
- -
-7
1
-12
1
32
- -
Net Income, GAAP
65
14.49
36.78
- -
- -
26.69
- -
27.39
21.8
- -
Effective Tax Rate (%)
2.79
11.72
10.71
-0.04
-4.86
0.26
-6.03
0.5
14.48
- -
Profit Margin (%)
194
292
203
153
141
182
173
262
279
260
Working Capital
- -
4
31
29
25
79
66
79
43
63
LT Debt
243
385
382
372
364
451
434
421
453
431
Total Equity
- -
3.31
1.01
- -
- -
-0.05
- -
-0.62
5.86
- -
Return on Invested Capital (%)
- -
7.39
6.13
- -
- -
0.31
- -
0.39
6.51
- -
Return on Capital (%)
- -
7.35
5.19
-0.02
-1.96
0.12
-2.61
0.23
7.38
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
8
3
8
LT Borrowings
- -
- -
- -
LT Finance Leases
43
43
63
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
676
618
534

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
294
320
330
Cash, Cash Equivalents & STI
155
205
209
Accounts Receivable, Net
59
26
32
Inventories
56
62
64
Total Current Liabilities
41
41
70
Payables & Accruals
- -
- -
- -
ST Debt
8
3
8
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.54%
7.67%
Free Cash Flow
- -
161.41%
433.43%
Net Income, GAAP
- -
2,557.88%
3,118.56%
Sales/Revenue/Turnover
- -
7.94%
10.42%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
202
2025
- -
- -
223
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.03
2025
- -
- -
1.09
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Bioray Biotech Co., Ltd. is dedicated to the research, development, manufacturing, and commercialization of biological and health-enhancing products. The company's portfolio features specialized functional probiotics, unique medicinal fungi, and cutting-edge immune cell preparations. Bioray Biotech further extends its services to include advanced functional medical testing and comprehensive cell storage solutions. Established in 2005, the firm emphasizes a commitment to comprehensive immunity protection and precision medicine, utilizing patented strains and scientific validation to deliver natural, evidence-backed health and wellness solutions. Headquartered in Pingtung, Taiwan, the company also operates a precision testing laboratory and facilities for immune cell therapy.